NEW YORK – Natera said on Wednesday that it has added three recently issued target amplification patents relating to its oncology liquid biopsy test technology to its ongoing patent infringement lawsuit against ArcherDx.
Natera filed its suit against ArcherDx in the US District Court of Delaware on Jan. 27, alleging that ArcherDx infringed its US Patent No. 10,538,814, which relates to target amplification.
The company has now added US Patents No. 10,557,172 and No. 10,597,708 – both titled "Methods for simultaneous amplification of target loci" and issued Feb. 11 and March 24, respectively – as well as US Patent No. 10,590,482, titled "Amplification of cell-free DNA using nested PCR" and issued March 17. All three patents cover methods for amplifying and sequencing nucleic acids.
Natera claims ArcherDx infringes these patents by selling, manufacturing, or using various oncology products, including products in the personalized liquid biopsy space. The company is seeking both injunctive relief and monetary damages.
Natera's Signatera cell-free circulating tumor DNA blood test is being used in patients with colorectal cancer and other cancer types and received breakthrough designation from the US Food and Drug Administration last year.
ArcherDx sells LiquidPlex research-use-only panels for targeted sequencing of cell-free circulating tumor DNA from 28 genes commonly associated with solid tumors, using its anchored multiplex PCR (AMP) target enrichment method.